Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Richard Levy

Cardiovascular Disease San Francisco, CA Medical Doctor

NPI 1356421408 CMS profile 196906

3580 California St, Ste 302, San Francisco, CA 94118

Open in the dashboard

General payments

$19,037

443 records reported · program years 2019–2025

Research payments

$4,663

Paid to them · 4 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Richard Levy of San Francisco, CA is reported in the CMS Open Payments database as having received $19,037 across 443 general payments and $4,663 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,102 41
2024 General $1,027 35
2023 General $1,669 72
2022 General $1,628 72
2022 Research $1,513 2
2021 General $5,342 99
2021 Research $1,050 1
2020 General $5,766 58
2020 Research $2,100 1
2019 General $2,503 66

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Richard Levy
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Richard Levy were reported at $1,102. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Richard Levy Cardiovascular Disease median Middle half National median
2019 $2,503 $450 $127–$1,392 $163
2020 $5,766 $242 $77–$751 $114
2021 $5,342 $335 $101–$1,037 $132
2022 $1,628 $395 $121–$1,211 $149
2023 $1,669 $443 $136–$1,283 $160
2024 $1,027 $450 $136–$1,323 $164
2025 $1,102 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $9,596 49 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $1,400 48 payments
  3. Novo Nordisk Inc $1,096 50 payments
  4. Sanofi-Aventis U.S. LLC $892 36 payments
  5. E.R. Squibb & Sons, L.L.C. $829 54 payments
  6. Novartis Pharmaceuticals Corporation $784 29 payments
  7. Lilly USA, LLC $480 6 payments
  8. Amgen Inc. $474 12 payments
  9. Amarin Pharma Inc. $458 32 payments
  10. Janssen Pharmaceuticals, Inc $426 17 payments
  11. Other $2,602 110 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,373 419 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $8,350 9 payments
  3. Education $296 13 payments
  4. Travel and Lodging $18 2 payments
Products named General payments · program years 2019–2025
  1. FARXIGA $9,158 35 payments
  2. JARDIANCE $1,189 44 payments
  3. ENTRESTO $634 23 payments
  4. Ozempic $540 36 payments
  5. ELIQUIS $535 36 payments
  6. RYBELSUS $460 33 payments
  7. XARELTO $455 19 payments
  8. Vascepa $425 31 payments
  9. MULTAQ $422 20 payments
  10. Kerendia $385 11 payments
  11. Other $5,814 225 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Neurocrine Biosciences, Inc. $4,663 4 payments

Prescribing to Medicare patients

Part D · data year 2024 · 69 drugs

Part D claims

3,720

Median for Cardiology: 2,533

Drug cost

$396,523

Median for Cardiology: $485,213

Branded share of claims

19.5%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 83 $77,112
Xarelto Rivaroxaban Brand 66 $69,809
Jardiance Empagliflozin Brand 41 $39,146
Farxiga Dapagliflozin Propanediol Brand 51 $35,033
Entresto Sacubitril/Valsartan Brand 27 $26,479
Multaq Dronedarone Hcl Brand 22 $17,779
Mounjaro Tirzepatide Brand 15 $14,771
Ozempic Semaglutide Brand 15 $14,132
Januvia Sitagliptin Phosphate Brand 14 $12,342
Brilinta Ticagrelor Brand 19 $11,201

The 10 drugs with the highest cost, of 69 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 22 billing codes

Paid by Medicare

$100,970

Of which drugs: $1,217

Medicare patients

224

Average age 79

Services billed

1,031

109 women, 115 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 49%
Arthritis 42%
Ischemic heart disease 26%
Atrial fibrillation 20%
Depression 17%
Heart failure 16%
Cancer 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 14 14 $1,145

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FARXIGA
  • AstraZeneca Pharmaceuticals LP $137
$137 51 —
Wegovy
  • Novo Nordisk Inc $136
$136 — —
MOUNJARO
  • Lilly USA, LLC $98
$98 15 —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $70
$70 — —
RYBELSUS
  • Novo Nordisk Inc $59
$59 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

447 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record